Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Cosmo Pharmaceuticals released pivotal phase 3 findings on clascoterone treatment, a potential first-in-class medication designed to target androgenetic alopecia.

Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Once-daily oral baricitinib was shown to result in meaningful hair regrowth after 1 year in adolescent patients with alopecia areata.

BRAVE-AA-PEDS: Baricitinib Leads to Hair Regrowth in Adolescents with Alopecia Areata

This systematic review and network meta-analysis was conducted to establish a hierarchy among approved oral JAK inhibitors for severe alopecia areata in adults.

Deuruxolitinib Shows Greatest Short-Term Efficacy Among JAKis for Severe Alopecia Areata

These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.


ALLEGRO-2b/3: Post-Hoc Analysis Suggests Alopecia Areata Improves With Ritlecitinib

This analysis highlights patients with alopecia areata who did not respond to 1 or more JAK inhibitors but saw regrowth after switching to a different JAKi.

Hair Regrowth Observed After Switching Between JAK Inhibitors in Severe Alopecia

This review explores the safety of oral JAK inhibitors in inflammatory skin conditions, with 43 real-world studies being highlighted.

Real-World Findings on Incidence of Adverse Events Highlighted for JAK Inhibitors

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

EADV 2025 Congress Recap: 14 Late-Breaking Trials to Know

New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.